


ANDA: Abbreviated New Drug Application; **API:** Active Pharmaceutical Ingredient; **BMI:** Body Mass Index; **CKD:** chronic kidney disease; **DNA:** Deoxyribonucleic acid; **EU-M4all:** The European Medicines Agency (EMA), in cooperation with the World Health Organization (WHO), can provide scientific opinions on high priority human medicines, including vaccines, that are intended for markets outside of the European Union (EU). The procedure is called EU-Medicines for all or 'EU-M4all'; **GLP-1 RA:** Glucagon-like peptide-1 receptor agonist; **LMICs:** low-income (LICs), lower middle-income and upper middle-income countries as per World Bank classification; **T2DM:** Type 2 diabetes mellitus.



ANDA: Abbreviated New Drug Application; **API:** Active Pharmaceutical Ingredient; **BMI:** Body Mass Index; **CKD:** chronic kidney disease; **CVD:** cardiovascular disease; **DNA:** Deoxyribonucleic acid; **EU-M4all:** The European Medicines Agency (EMA), in cooperation with the World Health Organization (WHO), can provide scientific opinions on high priority human medicines, including vaccines, that are intended for markets outside of the European Union (EU). The procedure is called EU-Medicines for all or 'EU-M4all'; **GLP-1 RA:** Glucagon-like peptide-1 receptor agonist; **LMICs:** low-income (LICs), lower middle-income and upper middle-income countries as per World Bank classification; **MACE:** major adverse cardiovascular events; **SGLT2i:** Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors also known as "gliflozins"; **SNAC:** Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate; **Swissmedic MAGHP:** Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products; **T2DM:** Type 2 diabetes mellitus; **USFDA:** The United States Food and Drug Administration